AzTrials
AzTrials

High Background Uptake on MBINCT02979301

Impact of Low-dose Tamoxifen on BPU

A study testing Tamoxifen in people with High Background Uptake on MBI, run by Mayo Clinic at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The study will examine whether changes in background parenchymal uptake (BPU) on molecular breast imaging (MBI) can be induced by short-term use of low-dose tamoxifen. Women who have previously had high BPU on MBI will be recruited. Read more about this study

Who is it for?
Ages 40 years and older, women onlyHealthy volunteers can take part
Conditions the study is for
High Background Uptake on MBI
What is being tested?
Tamoxifen
Could I receive a placebo?
No, everyone receives an active treatment
How many people
22 participants
Where
1 siteUnited States
Study dates
1 Mar 2017to 1 Nov 2018
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 years and older
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Inclusion Criteria:The following are requirements for entry into the study:

  1. Female, age 40 or older at the time of enrollment
  2. Most recent MBI examination, performed within 3 years of enrollment, showed moderate or marked background parenchymal uptake
  3. Mammogram performed within 12 months prior to enrollment that is available for comparison
  4. Willing and able to return for MBI following 30 days of low-dose tamoxifen
  5. If able to become pregnant
  6. Negative pregnancy test within 48 hours prior to study MBI exam(s)
  7. Agrees to avoid pregnancy during the study and for at least 2 months after study participation ends, by abstinence, barrier method, or nonhormonal contraception.
  8. Understands and signs the consent form -

Exclusion Criteria:Subjects will be excluded if any of the following characteristics are present:

  1. Evidence of suspected breast disease as defined by positive findings or recommendation for short-interval follow-up on most recent breast imaging (including mammography, MBI, MRI, ultrasound, etc.) not yet resolved prior to enrollment 2) Breast biopsy or breast surgery performed 6 months prior to enrollment 3) Bilateral breast implants or status post-bilateral prophylactic mastectomy 4) Pregnant or lactating 5) Current or recent use (within 6 months prior to enrollment) of any of the following drugs:
  2. Systemic hormonal therapy (oral or transdermal patch formulations)
  3. Hormonal contraception (oral, transdermal, implanted, or injected formulations)
  4. Selective estrogen receptor modulators (tamoxifen, raloxifene, or toremifene)
  5. Aromatase inhibitors (anastrazole, letrozole, or exemestane)
  6. GnRH analogs
  7. Prolactin inhibitors
  8. Androgens or antiandrogens
  9. Anticoagulants or "blood thinners" (warfarin, heparin, rivaroxaban and other novel anticoagulants)
  10. Drugs known to be strong inhibitors of CYP2D6, the major P450 enzyme that metabolizes tamoxifen, including:
  • bupropion (Wellbutrin)
  • fluoxetine (Prozac)
  • paroxetine (Paxil)
  • quinidine (Quinidex) 6) Personal history of any type of malignancy, with the exclusion of non-melanoma skin cancer, diagnosed prior to enrollment 7) Personal history or strong family history of blood clots in legs or lungs (also known as deep vein thrombosis or pulmonary embolism) 8) Personal history of transient ischemic attack (TIA) or cerebrovascular accident (CVA) 9) Active proliferative disorders of the endometrium such as atypical hyperplasia, history of active endometriosis, unresected polyps 10) Any type of retinal disorders or severe cataract 11) Current or former smoker 12) Known carrier of BRCA1 or BRCA2 genetic mutation or known DNA repair defect.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Mayo Clinic

    Rochester, Minnesota, 55905

Other trials in United States

About this study

Official title: Low-Dose Tamoxifen to Reduce High Background Parenchymal Uptake on Molecular Breast Imaging

The study will examine whether changes in background parenchymal uptake (BPU) on molecular breast imaging (MBI) can be induced by short-term use of low-dose tamoxifen. Women who have previously had high BPU on MBI will be recruited. Participants will take low-dose tamoxifen for a 30-day period, with post-tamoxifen MBI in order to investigate the impact of tamoxifen on BPU.

Being tested
Tamoxifen

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TamoxifenDrug

    5 mg or 10 mg tamoxifen per day for 30 days.

Study groups in NCT02979301
Study groupRoleWhat they receive
Tamoxifen 5 mg/dayExperimentalWomen with high background uptake on MBI take 5 mg tam per day for 30 days.
Receives: Drug: Tamoxifen
Tamoxifen 10 mg/dayExperimentalWomen with high background uptake on MBI take 10 mg tam per day for 30 days.
Receives: Drug: Tamoxifen

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Background Parenchymal Uptake (BPU) on Molecular Breast Imaging (MBI)

    An image analysis tool to obtain a quantitative measure of background parenchymal uptake (BPU) was applied to pre-tamoxifen and post-tamoxifen MBI exams. The percent change in BPU from pre-tamoxifen to post-tamoxifen MBI was determined.

    Measured: 30 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Dec 2016 (estimated)
  2. Study start1 Mar 2017
  3. Primary completion25 Feb 2018
  4. Study completion1 Nov 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Non-randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
22 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02979301
Sponsor's protocol ID
IRB 16-008736
Status last verified
Apr 2019
First submitted
29 Nov 2016
Last updated
16 Jul 2019
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Hruska CB, Hunt KN, Conners AL, Geske JR, Brandt KR, Degnim AC, Vachon CM, O'Connor MK, Rhodes DJ. Impact of short-term low-dose tamoxifen on molecular breast imaging background parenchymal uptake: a pilot study. Breast Cancer Res. 2019 Mar 8;21(1):38. doi: 10.1186/s13058-019-1120-5.

    PubMed 30850011

Questions about this trial

What is this clinical trial studying?

A study testing Tamoxifen in people with High Background Uptake on MBI, run by Mayo Clinic at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 Jul 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 16 Jul 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Background Parenchymal Uptake (BPU) on Molecular Breast Imaging (MBI) (time frame: 30 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02979301, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in